AAAAAA

   
Results: 1-22 |
Results: 22
To IRB or not to IRB? That is no longer the question
Authors: Lehman, CM Rodgers, GM
Citation: Cm. Lehman et Gm. Rodgers, To IRB or not to IRB? That is no longer the question, AM J CLIN P, 115(2), 2001, pp. 187-191
Update on selected inherited venous thrombotic disorders
Authors: Robetorye, RS Rodgers, GM
Citation: Rs. Robetorye et Gm. Rodgers, Update on selected inherited venous thrombotic disorders, AM J HEMAT, 68(4), 2001, pp. 256-268
Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin
Authors: Busby, LT Weyman, A Rodgers, GM
Citation: Lt. Busby et al., Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin, AM J HEMAT, 67(1), 2001, pp. 54-56
Management of thrombosis in women with antiphospholipid syndrome
Authors: Chandramouli, NB Rodgers, GM
Citation: Nb. Chandramouli et Gm. Rodgers, Management of thrombosis in women with antiphospholipid syndrome, CLIN O GYNE, 44(1), 2001, pp. 36-47
Discontinuation of the bleeding time test without detectable adverse clinical impact
Authors: Lehman, CM Blaylock, RC Alexander, DP Rodgers, GM
Citation: Cm. Lehman et al., Discontinuation of the bleeding time test without detectable adverse clinical impact, CLIN CHEM, 47(7), 2001, pp. 1204-1211
Discontinuation of the bleeding time test without detectable adverse clinical impact (vol 47, pg 1204, 2001)
Authors: Lehman, CM Blaylock, RC Alexander, DP Rodgers, GM
Citation: Cm. Lehman et al., Discontinuation of the bleeding time test without detectable adverse clinical impact (vol 47, pg 1204, 2001), CLIN CHEM, 47(11), 2001, pp. 2077-2077
New commercially available lyophilized controls for the heparin-dependent antibody test
Authors: Rodgers, GM
Citation: Gm. Rodgers, New commercially available lyophilized controls for the heparin-dependent antibody test, LAB MED, 32(8), 2001, pp. 420-420
Commercial controls for the heparin-dependent antibody test
Authors: Rodgers, GM
Citation: Gm. Rodgers, Commercial controls for the heparin-dependent antibody test, LAB MED, 32(5), 2001, pp. 247-247
Identity of the tissue factor-inducing activity in human plasma
Authors: Rodgers, GM
Citation: Gm. Rodgers, Identity of the tissue factor-inducing activity in human plasma, BR J HAEM, 114(2), 2001, pp. 485-485
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease
Authors: Merli, G Spiro, TE Olsson, CG Abildgaard, U Davidson, BL Eldor, A Elias, D Grigg, A Musset, D Rodgers, GM Trowbridge, AA Yusen, RD Zawilska, K
Citation: G. Merli et al., Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease, ANN INT MED, 134(3), 2001, pp. 191-202
Heparin-induced thrombocytopenia is rare in pregnancy
Authors: Fausett, MB Vogtlander, M Lee, RM Esplin, MS Branch, DW Rodgers, GM Silver, RM
Citation: Mb. Fausett et al., Heparin-induced thrombocytopenia is rare in pregnancy, AM J OBST G, 185(1), 2001, pp. 148-152
Genetic testing in autopsies - Reply
Authors: Florell, SR Rodgers, GM
Citation: Sr. Florell et Gm. Rodgers, Genetic testing in autopsies - Reply, AM J CLIN P, 113(2), 2000, pp. 311-312
Utilization and outcomes of enoxaparin treatment for deep-vein thrombosis in a tertiary-care hospital
Authors: Gilbert, KB Rodgers, GM
Citation: Kb. Gilbert et Gm. Rodgers, Utilization and outcomes of enoxaparin treatment for deep-vein thrombosis in a tertiary-care hospital, AM J HEMAT, 65(4), 2000, pp. 285-288
Detection of occult cobalamin deficiency by magnetic resonance imaging
Authors: Yu, MK Rodgers, GM
Citation: Mk. Yu et Gm. Rodgers, Detection of occult cobalamin deficiency by magnetic resonance imaging, AM J HEMAT, 65(1), 2000, pp. 83-84
Prolonged immunoglobulin and platelet infusion for treatment of immune thrombocytopenia
Authors: Chandramouli, NB Rodgers, GM
Citation: Nb. Chandramouli et Gm. Rodgers, Prolonged immunoglobulin and platelet infusion for treatment of immune thrombocytopenia, AM J HEMAT, 65(1), 2000, pp. 85-86
Evidence of increased angiogenesis in patients with acute myeloid leukemia
Authors: Hussong, JW Rodgers, GM Shami, PJ
Citation: Jw. Hussong et al., Evidence of increased angiogenesis in patients with acute myeloid leukemia, BLOOD, 95(1), 2000, pp. 309-313
Immunosuppressive effects of factor IX products: an in vitro study
Authors: Grosset, AB McGregor, JR Samlowski, WE Rodgers, GM
Citation: Ab. Grosset et al., Immunosuppressive effects of factor IX products: an in vitro study, HAEMOPHILIA, 5(6), 1999, pp. 416-425
Factor V-Leiden: Death and DNA
Authors: Florell, SR Rodgers, GM
Citation: Sr. Florell et Gm. Rodgers, Factor V-Leiden: Death and DNA, AM J CLIN P, 111(3), 1999, pp. 302-303
Dithiocarbamates ameliorate the effects of endotoxin in a rabbit model of disseminated intravascular coagulation
Authors: Drollinger, AG Netser, JC Rodgers, GM
Citation: Ag. Drollinger et al., Dithiocarbamates ameliorate the effects of endotoxin in a rabbit model of disseminated intravascular coagulation, SEM THROMB, 25(4), 1999, pp. 429-433
Inappropriate use of enoxaparin in the treatment of deep-vein thrombosis
Authors: Rodgers, GM
Citation: Gm. Rodgers, Inappropriate use of enoxaparin in the treatment of deep-vein thrombosis, N ENG J MED, 340(1), 1999, pp. 62-62
Overview of platelet physiology and laboratory evaluation of platelet function
Authors: Rodgers, GM
Citation: Gm. Rodgers, Overview of platelet physiology and laboratory evaluation of platelet function, CLIN O GYNE, 42(2), 1999, pp. 349-359
Activated partial thromboplastin time
Authors: Rodgers, GM
Citation: Gm. Rodgers, Activated partial thromboplastin time, LAB MED, 30(10), 1999, pp. 640-640
Risultati: 1-22 |